Application and mechanism of imiquimod in skin tumor

doi:10.3760/cma.j.issn.1673422X.2016.12.019

Abstract

ZHANG Fu-He, SHI Lei, LUO Min, WANG Xiu-Li. Application and mechanism of imiquimod in skin tumor[J]. Journal of International Oncology, 2016, 43(12): 953-955.

［1］ Lecluse LL, Spuls PI. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basalcell carcinoma: a single blind, noninferiority, randomised controlled trial: a critical appraisal［J］. Br J Dermatol, 2015, 172(1): 810. DOI: 10.1111/bjd.13460. ［2］ Papakostas D, Stockfleth E. Topical treatment of basal cell carcinoma with the immune response modifier imiquimod［J］. Future Oncol, 2015, 11(22): 29852990. DOI: 10.2217/fon.15.192. ［3］ Kawasaki M, Kawakami N, Kawai K, et al. Cutaneous mucormycosis in bone marrow transplantation recipients［J］. Eur J Dermatol, 2012, 22（4）: 578579.DOI: 10.1684/ejd.2012.1770. ［4］ Aspord C, Tramcourt L, Leloup C, et al. Imiquimod inhibits melanoma development by promoting pDC cytotoxic functions and impeding tumor vascularization［J］. J Invest Dermatol, 2014, 134（10）: 25512561. DOI: 10.1038/jid.2014.194. ［5］ Kim JM, Lee HJ, Kim SH, et al. Efficacy of 5% imiquimod cream on vulvar intraepithelial neoplasia in Korea: pilot study［J］. Ann Dermatol, 2015, 27（1）: 6670. DOI: 10.5021/ad.2015.27.1.66. ［6］ Samo M, Choudhary NR, Riebe KJ，et al. Immunization with the Haemophilus ducreyi trimeric autotransporter adhesin DsrA with alum, CpG or imiquimod generates a persistent humoral immune response that recognizes the bacterial surface［J］. Vaccine， 2016， 34(9): 11931200. DOI: 10.1016/j.vaccine.2016.01.024. ［7］ Bubna AK. Imiquimodits role in the treatment of cutaneous malignancies［J］. Indian J Pharmacol， 2015， 47(4): 354359. DOI: 10.4103/02537613.161249. ［8］ Hemmi H, Kaisho T, Takeuchi O, et al. Small antiviral compounds activate immune cells via the TLR7 MyD88dependent signaling pathway［J］. Nat Immunol, 2002, 3（2）: 196200. DOI: 10.1038/ni758. ［9］ Singh M, Khong H, Dai Z, et al. Effective innate and adaptive antimelanoma immunity through localized TLR7/8 activation［J］. J Immunol, 2014, 193（9）: 47224731. DOI: 10.4049/jimmunol.1401160. ［10］ Johnston D, Bystryn JC. Topical imiquimod is a potent adjuvant to a weaklyimmunogenic protein prototype vaccine［J］. Vaccine, 2006, 24（11）: 19581965. DOI: 10.1016/J.vaccine.2005.10.045. ［11］ RoldánMarín R, ToussaintCaire S. Imiquimod 5% as adjuvant therapy for incompletely excised infiltrative nodular basal cell carcinoma and dermoscopy to monitor treatment response［J］. Dermatol Ther (Heidelb), 2015, 5(4): 265272. ［12］ Huang SW, Chang SH, Mu SW， et al.Imiquimod activates p53dependent apoptosis in a human basal cell carcinoma cell line［J］. J Dermatol Sci, 2016, 81(3):182191. DOI: 10.1016/j.jdermsci.2015.12.011. ［13］ Huang SW, Kao JK, Wu CY, et al. Targeting aerobic glycolysis and HIF1alpha expression enhance imiquimodinduced apoptosis in cancer cells［J］. Oncotarget, 2014, 5（5）: 13631381. DOI: 10.18632/oncotarget.1734. ［14］ Sohn KC, Li ZJ, Choi DK, et al. Imiquimod induces apoptosis of squamous cell carcinoma (SCC) cells via regulation of A20［J］. PLoS One, 2014, 9: e95337. DOI: 10.1371/journal.pone.0095337. e Collection 2014. ［15］ Huang SW, Chang CC, Lin CC, et al. Mcl1 determines the imiquimodinduced apoptosis but not imiquimodinduced autophagy in skin cancer cells［J］. J Dermatol Sci， 2012， 65(3): 170178. DOI: 10.1016/j.jdermsci.2011.11.001. ［16］ Wang ST, Huang SW, Kao JK, et al. Imiquimodinduced AMPK activation causes translation attenuation and apoptosis but not autophagy［J］. J Dermatol Sci, 2015, 78（2）: 108116. DOI: 10.1016/j.jdermsci.2015.02.008. ［17］ Ahn MY, Kwon SM, Cheong HH, et al. Tolllike receptor 7 agonist, Imiquimod, inhibits oral squamous carcinoma cells through apoptosis and necrosis［J］. J Oral Pathol Med, 2012, 41（7）: 540546. DOI: 10.1111/j.16000714.2012.01158.x. ［18］ Aspord C, Tramcourt L, Leloup C, et al. Imiquimod inhibits melanoma development by promoting pDC cytotoxic functions and impeding tumor vascularization［J］. J Invest Dermatol, 2014, 134（10）: 25512561. DOI: 10.1038/jid.2014.194. ［19］ Paul SP. Topical treatment of skin cancers and the risks of “fighting fire with fire”［C］. In: Clinical Cases in Skin Cancer Surgery and Treatment. Springer, 2016: 115125. DOI: 10.1007/9783319209371_11. ［20］ Yin T, He S, Wang Y. Toll like receptor 7/8 agonist, R848, exhibits antitumoral effects in a breast cancer model［J］. Mole Med Rep, 2015, 12(3): 35153520. DOI: 10.3892/mmr.2015.3885. ［21］ Savarese I, Papi F, D′Errico A, et al. Acral lentiginous melanoma treated with topical imiquimod cream: possible cooperation between drug and tumour cells［J］. Clin Exp Dermatol, 2015, 40(1): 2730. DOI: 10.1111/ced.12469.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Chen Hongjian, Zhang Suqing. Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients [J]. Journal of International Oncology, 2024, 51(6): 344-349.
[5]	Guo Zehao, Zhang Junwang. Role of PFDN and its subunits in tumorigenesis and tumor development [J]. Journal of International Oncology, 2024, 51(6): 350-353.
[6]	Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358.
[7]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[8]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[9]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Liu Jing, Liu Qin, Huang Mei. Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm [J]. Journal of International Oncology, 2024, 51(5): 267-273.
[12]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[13]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.
[14]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi. Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer [J]. Journal of International Oncology, 2024, 51(5): 286-291.
[15]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying. Research progress of habitat analysis in radiomics of malignant tumors [J]. Journal of International Oncology, 2024, 51(5): 292-297.

Application and mechanism of imiquimod in skin tumor

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments